Results 271 to 280 of about 31,072 (344)
Central nervous system involvement in cardiac amyloidosis: Redefining the heart‐brain axis
Central nervous system involvement in cardiac amyloidosis. Amyloidosis is a systemic disease that can directly affect the central nervous system. Furthermore, the amyloid cardiomyopathy can indirectly affect the central nervous system by inducing systemic hypoperfusion and increasing the risk of acute ischaemic stroke.
Domenico Mario Giamundo +3 more
wiley +1 more source
Biomechanical bite simulation in Eucyon davisi (Mammalia, Canidae) and comparison with extant Canids. [PDF]
Emanuele P +3 more
europepmc +1 more source
Abstract Background Temporohyoid osteoarthropathy (THO) is characterised by bone proliferation and cartilage ossification caused by infectious and degenerative conditions, amongst others. Objectives To describe the variable appearance of the temporohyoid joint (THJ) on computed tomography (CT) and investigate associations between CT changes and ...
Rupert F. Dash +3 more
wiley +1 more source
Meningeal lymphatics as a therapeutic target for neurodegenerative disorders. [PDF]
Feng Y +6 more
europepmc +1 more source
Abstract Objective This study evaluated cranial magnetic resonance imaging (MRI) signs in patients with post‐dural puncture headache (PDPH) using an established assessment score developed for spontaneous intracranial hypotension (Bern score). We hypothesize that patients with chronic PDPH do not have typical imaging features of intracranial hypotension.
Charlotte Zander +9 more
wiley +1 more source
Jugular Eagle Syndrome as a Rare Cause of Cerebral Venous Sinus Thrombosis: A Case Report and Treatment Considerations. [PDF]
Hammed A +3 more
europepmc +1 more source
Can atogepant be a preventive treatment for cluster headache?—Insights from a case series
Abstract Cluster headache (CH) is a disabling primary headache disorder with limited therapeutic options. Calcitonin gene‐related peptide (CGRP) is known to be involved in CH pathophysiology; however, except for galcanezumab (300 mg) in episodic CH, anti‐CGRP monoclonal antibodies did not reduce CH attacks in randomized clinical trials. Atogepant is an
Catarina Serrão +3 more
wiley +1 more source
Multiple Dural Venous Sinus Thromboses in a Young Female Presenting With Refractory Headaches. [PDF]
Bharadwaj AS +3 more
europepmc +1 more source

